FDA approves Forest Labs' Daliresp to treat COPD
Links shared publicly online about this topic.
- 471total visits
FDA approves Forest Labs' Daliresp to treat COPD
View full resource at news-medical.net
Tags: COPD, Osteoporosis, Diet and Nutrition, Drug, FDA, Forest Laboratories, News
Most Recently Shared on March 1, 2011 at 11:46 am By:
Pregnancy News: FDA approves Forest Labs' Daliresp to treat COPD: Forest Laboratories, Inc. announced today that... http://bit.ly/gN2zHY
Also Shared By:
Forest, Nycomed Win FDA Approval for Daliresp Lung Medicine - Bloomberg
bloomberg.com — “Forest Laboratories Inc. and Nycomed A/S won U.S. approval for the Daliresp drug to treat chronic obstructive pulmonary disease, also known as smokers--™ cough, after regulators asked for more information on the product last year.” View full resource at bloomberg.com
Most Recently Shared on March 2, 2011 at 2:55 pm By:
Thoughts on roflumilast FDA approval for COPD, despite ad comm 10-5 vote against? http://bloom.bg/fCJFvh
FDA Approves Forest Laboratories Drug To Treat Lung Disease - WSJ.com
online.wsj.com — “FDA Approves Forest Laboratories Drug To Treat Lung Disease - WSJ.com” View full resource at online.wsj.com
Most Recently Shared on March 2, 2011 at 1:58 pm By:
FDA aproves long term use med, Daliresp, which impacts inflammatory process involved w/ airway constriction in COPD http://on.wsj.com/eqm9xv
Forest, Nycomed win narrow FDA approval on new COPD drug - FierceBiotech
fiercebiotech.com — “Forest Labs and Switzerland's Nycomed have managed to overcome some sharp criticism from a panel of experts and win a narrow approval of Daliresp (roflumilast) to prevent the exacerbation of COPD. Read more...” View full resource at fiercebiotech.com
Most Recently Shared on March 1, 2011 at 3:31 pm By:
Forest, Nycomed win narrow FDA approval on new COPD drug. http://bit.ly/hi1BcL
Advertisement


News-Medical.Net
@Osteoporosis_nt
Osteoporosis News: FDA approves Forest Labs' Daliresp to treat COPD: Forest Laboratories, Inc. announced today t... http://bit.ly/gN2zHY
1 year ago...